Typically, making a drug begins with identifying a protein associated with human disease. These proteins are known as “targets.” When it is confirmed that a target plays a role in a disease, an experiment known as a high-throughput screen is conducted to find a chemical compound or antibody that binds or “hits” the target in a way that alters the disease. Once chemical compounds or antibodies are identified by their binding to a target, these hits are enhanced to improve their safety and effectiveness. The resulting chemical compound or antibody becomes a drug candidate.
Novartis Oncology has a broad, deep pipeline that encompasses a spectrum of therapeutic approaches. Learn about our key therapeutic targets:
- RAS-RAF-MEK-ERK pathway inhibitors
- FGFR inhibitors
- Monoclonal antibodies
- PI3K pathway inhibitors
- HSP90 inhibitors
- Smoothened (Smo) receptor inhibitors
- Multiple pathway inhibitors
- Other novel targeted agents
Our research strategy leverages these and other biomarkers and increasingly precise drug development focused on individual patients. Learn more about precision oncology.